News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AdipoGenix, Inc. Inks $8.25 Million In Commitments On Its Way To $13 Million Series A



10/19/2005 5:09:13 PM

6/20/2005 AdipoGenix Inc., a biopharmaceutical company developing small molecule therapeutics for the treatment of obesity and Type-2 diabetes, has secured $8.25 million of committed capital towards a $13 million Series A round, President and Chief Executive Ed Cannon told VentureWire.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES